The MosaiQ AiPlex CD is designed to improve the accuracy and speed of celiac disease diagnosis while simplifying laboratory workflows The MosaiQ AiPlex CD multiplex assay, which received IVDR-CE mark ...
Manufacturing of Microarrays for European field trials planned to commence in early April MosaiQ™ instrument development completed and formal validation has commenced Completion of European field ...
The MosaiQ AiPlex CTDplus multiplex assay, which received IVDR-CE mark certification in February 2025, is designed to improve the accuracy and speed of systematic connective tissue disease diagnosis ...
JERSEY, Channel Islands, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced the company received feedback from the European ...
The Company recently completed a study that measured the sensitivity of tests performed using its MosaiQ MDS microarray. The Company found the study results to be highly encouraging because they show ...
The MosaiQ instrument is a next-generation, continuous random-access immunoassay platform offering labs automation, simple workflows, fast, multiplexed results and actionable insights for ...
As part of consolidating the cancer care of four Western Australian public services into a single, multi-disciplinary facility, the clinics will transition from their existing oncology information ...
JERSEY, Channel Islands, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (Quotient or the Company), a commercial-stage diagnostics company, today reported the successful conclusion ...
Molecular Disease Screening Microarray Feasibility Study Completed Initial Serological Disease Screening FDA 510(k) Submission Accepted Commencement of EU Expanded Immunohematology Field Trial ...
JERSEY, Channel Islands, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company headquartered in Eysins, Switzerland, today announced its attendance ...
CROISSY-BEAUBOURG, France--(BUSINESS WIRE)--Regulatory News: THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and theranostics, today ...
EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ — AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® Celiac Disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback